Diseases of Pulmonary Vasculature

Featured Article

Societies Publish Appropriate Use Criteria for Multimodality Imaging in Nonvalvular Heart Disease

Societies Publish Appropriate Use Criteria for Multimodality Imaging in Nonvalvular Heart Disease

Updated appropriate use criteria addresses the use of multimodality imaging for evaluation of cardiac structure and function in nonvalvular heart disease.

Latest Features

Societies Publish Appropriate Use Criteria for Multimodality Imaging in Nonvalvular Heart Disease

Societies Publish Appropriate Use Criteria for Multimodality Imaging in Nonvalvular Heart Disease

Updated appropriate use criteria addresses the use of multimodality imaging for evaluation of cardiac structure and function in nonvalvular heart disease.

Pulmonary Hypertension Screening Adaptations for Adult Congenital Heart Disease

Pulmonary Hypertension Screening Adaptations for Adult Congenital Heart Disease

Because standardized approaches for echocardiographic screening are impractical for certain subgroups of people with congenital heart disease, experts offered screening adaptations for pulmonary hypertension.

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.

Improving Risk Stratification, Diagnostic Accuracy in PAH With Cardiopulmonary Exercise Testing

Improving Risk Stratification, Diagnostic Accuracy in PAH With Cardiopulmonary Exercise Testing

Cardiopulmonary exercise testing can be an important diagnostic and prognostic tool in pulmonary arterial hypertension.

Connective Tissue Diseases in Comorbid PAH: A Case for Separating SSc, SLE

Connective Tissue Diseases in Comorbid PAH: A Case for Separating SSc, SLE

Recent evidence suggests that systemic sclerosis and systemic lupus erythematosus comorbid with pulmonary arterial hypertension should be considered separate diseases.

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.

Lung Transplantation in Pulmonary Arterial Hypertension: An Overview

Lung Transplantation in Pulmonary Arterial Hypertension: An Overview

Evaluating diagnosis and treatment options for pulmonary arterial hypertension.

Worsening Shortness of Breath in a 40-Year-Old Woman: A Case Study

Worsening Shortness of Breath in a 40-Year-Old Woman: A Case Study

A 40-year-old woman presents with worsening shortness of breath after being treated with long-acting nifedipine for 2 years.

Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

Exercise intolerance is a hallmark symptom of pulmonary arterial hypertension.

Diagnostic Value of Bronchoalveolar Lavage in Idiopathic Pulmonary Fibrosis

Diagnostic Value of Bronchoalveolar Lavage in Idiopathic Pulmonary Fibrosis

The diagnostic value of bronchoalveolar lavage in idiopathic pulmonary fibrosis is evaluated.

Latest News

IVC Filters May Increase Mortality Risk in Elderly Patients With PE

IVC Filters May Increase Mortality Risk in Elderly Patients With PE

The use of inferior vena cava filters may increase the risk for 30-day and 1-year mortality in elderly patients with acute pulmonary embolism.

Macitentan Not Superior to Placebo for Improving Exercise Capacity in Eisenmenger Syndrome

Macitentan Not Superior to Placebo for Improving Exercise Capacity in Eisenmenger Syndrome

Macitentan did not show superiority over placebo for change in exercise capacity in patients with Eisenmenger syndrome.

Treprostinil May Have Antithrombotic Effect in Pediatric Pulmonary Hypertension

Treprostinil May Have Antithrombotic Effect in Pediatric Pulmonary Hypertension

Treatment with treprostinil has demonstrated potential antithrombotic mechanisms of action in pediatric patients with pulmonary arterial hypertension.

Does Pre-Existing PH Affect Outcomes in Transcatheter Mitral Valve Repair?

Does Pre-Existing PH Affect Outcomes in Transcatheter Mitral Valve Repair?

Pre-existing pulmonary hypertension does not appear to affect outcomes in transcatheter mitral valve repair with the Mitraclip device.

PAH Survival May Increase Risk for Pulmonary Artery Aneurysms

PAH Survival May Increase Risk for Pulmonary Artery Aneurysms

The time course of pulmonary arterial hypertension was an independent risk factor for pulmonary artery aneurysms.

Prognostic Relevance of Cardiopulmonary Exercise Testing in Low-Risk Pulmonary Arterial Hypertension

Prognostic Relevance of Cardiopulmonary Exercise Testing in Low-Risk Pulmonary Arterial Hypertension

Combinations of VO2 and change in CI during follow-up visits are valuable prognosis markers in low-risk patients with PAH.

Exercise Capacity in CTEPH Improved With Treprostinil

Exercise Capacity in CTEPH Improved With Treprostinil

Compared with the low dose, high-dose subcutaneous treprostinil increased 6-minute walk distances in patients with chronic thromboembolic pulmonary hypertension.

PAH: An Under-Recognized Complication of Adult-Onset Still's Disease

PAH: An Under-Recognized Complication of Adult-Onset Still's Disease

PAH is an under-diagnosed complication of adult-onset Still disease.

Comorbid Mental Disorder Prevalence Higher in Pulmonary Arterial Hypertension

Comorbid Mental Disorder Prevalence Higher in Pulmonary Arterial Hypertension

People with pulmonary arterial hypertension display higher levels of depression and anxiety than previously estimated by healthcare workers.

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

FREEDOM-EV was an international, multicenter, randomized, double-blind, placebo-controlled trial (N=690) that randomized patients to 3 daily doses of Orenitram or placebo.

Pulmonary-Systemic Pulse Pressure Ratio Linked to PH Mortality

Pulmonary-Systemic Pulse Pressure Ratio Linked to PH Mortality

Patients with group 1 pulmonary hypertension who had a higher pulmonary-systemic pulse pressure ratio had a higher risk for mortality.

Segmental Pulmonary Hypertension: Management of New Classification

Segmental Pulmonary Hypertension: Management of New Classification

Segmental pulmonary hypertension can result from several conditions, such as complex pulmonary atresia, hemitruncus arteriosus, absence/atresia of a single pulmonary artery, and an anomalous pulmonary artery from the aorta feeding a single lung segment.

Implantable System for Remodulin Approved for Patients With PAH

Implantable System for Remodulin Approved for Patients With PAH

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.

Newly Diagnosed, Limitation-Free PH at Risk for Exercise Capacity Reductions

Newly Diagnosed, Limitation-Free PH at Risk for Exercise Capacity Reductions

Patients with World Health Organization Functional Class I pulmonary hypertension experienced a significant reduction in exercise capacity following the shuttle walk test.

Tricuspid Regurgitation Velocity Unreliable Indicator of Pulmonary Hypertension

Tricuspid Regurgitation Velocity Unreliable Indicator of Pulmonary Hypertension

Pulmonary hypertension was confirmed by invasive methods in 68% and 47% of patients with and without a measurable tricuspid regurgitation velocity, respectively.

Early Pulmonary Vascular Disease Onset Risk in Adults Born Preterm

Early Pulmonary Vascular Disease Onset Risk in Adults Born Preterm

Increased pulmonary pressures, right ventricular dysfunction, and a stiffer pulmonary vascular bed were typical characteristics of early pulmonary vascular disease onset in young adults who were born preterm.

PAH Mortality Rates Comparable With ERA or PDE5 Inhibitor Therapy

PAH Mortality Rates Comparable With ERA or PDE5 Inhibitor Therapy

There were no significant differences in pulmonary arterial hypertension survival based on therapy type, age was an important modifier.

Pulmonary Arterial Stiffness Related to mPAP and Heart Rate in Idiopathic PAH

Pulmonary Arterial Stiffness Related to mPAP and Heart Rate in Idiopathic PAH

Pulmonary arterial stiffness was related to mean pulmonary arterial pressure and heart rate in patients with untreated idiopathic pulmonary arterial hypertension.

Prognostic Model for Mortality in Pediatric Pulmonary Hypertension

Prognostic Model for Mortality in Pediatric Pulmonary Hypertension

The Pediatric Index Pulmonary Hypertension Intensive Care Mortality model was compared with the Pediatric Risk of Mortality 2 and 3 models to determine the best model for predicting mortality.

Sign Up for Free e-Newsletters